MS has plenty of drugs. This Ocrevus veteran sees what’s missing.

After helping launch a blockbuster Roche and Genentech therapy, Erik Lundgren is betting that Immunic's experimental drug can address persistent gaps in MS care, with pivotal trial results approaching

Source: PharmaVoice